Skip to main content
Genexine, Inc. logo

Genexine, Inc. — Investor Relations & Filings

Ticker · 095700 ISIN · KR7095700001 KO Manufacturing
Open in API
Filings indexed 341 across all filing types
Latest filing 2025-10-01 Capital/Financing Update
Country KR South Korea
Listing KO 095700

About Genexine, Inc.

http://www.genexine.com/

Genexine, Inc. is a clinical-stage biotechnology company focused on developing and commercializing immunotherapeutics and next-generation biologics. The company utilizes its proprietary hyFc® platform technology to create long-acting protein therapeutics. Its pipeline is led by GX-I7, a long-acting interleukin-7 designed to amplify T-cell counts for immuno-oncology applications. Other key assets in late-stage clinical trials include GX-E4, a long-acting treatment for anemia, and GX-H9 for growth hormone deficiency. Genexine's research and development efforts primarily target oncology and rare diseases.

Recent filings

Filing Released Lang Actions
증권발행결과(자율공시)
Capital/Financing Update Classification · 100% confidence The document is a short announcement about the issuance results of securities, specifically a private placement of convertible bonds. It includes details such as the type of security, issuance method, amount, dates, and listing status. The document length is only 650 characters, indicating it is a brief announcement rather than a full report. The content matches the description of a Capital/Financing Update, which covers company fundraising and capital structure changes. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2025-10-01 Korean
주요사항보고서(전환사채권발행결정)
Capital/Financing Update Classification · 95% confidence The document is a detailed disclosure about the issuance of convertible bonds (전환사채권 발행결정) by the company Genexine (주)제넥신. It includes specifics such as bond terms, conversion price adjustments, early redemption options, issuance amounts, and related parties. The document is addressed to the Financial Services Commission and Korea Exchange, indicating a regulatory filing related to capital raising. It is not a full financial report, earnings release, or management discussion. It is not a proxy, AGM material, or voting result. The content focuses on the decision and details of a bond issuance, which fits the category of Capital/Financing Update (CAP). The document length is over 14,000 characters, so it is not a mere announcement of a report but a substantive disclosure. Therefore, the correct classification is CAP with high confidence.
2025-09-24 Korean
[기재정정]주요사항보고서(전환사채권발행결정)
Capital/Financing Update Classification · 95% confidence The document is a detailed disclosure about the issuance of convertible bonds (전환사채권 발행결정) by the company Genexine (주)제넥신. It includes specifics such as the amount, terms, conversion price adjustments, early redemption options, use of proceeds, and lists of investors. The document is titled as a "주요사항보고서" which translates to a "Material Event Report" or "Major Event Report" in Korean regulatory filings. It is a regulatory announcement about a financing event, specifically the issuance of convertible bonds, including detailed terms and conditions. It is not a full financial report like an Annual Report (10-K) or Interim Report (IR), nor is it a simple announcement of a report publication. It is not a transcript, management change, or voting result. The content fits best under Capital/Financing Update (CAP) as it provides comprehensive information on a capital raising event through convertible bond issuance.
2025-09-24 Korean
주식매수선택권부여에관한신고
Regulatory Filings Classification · 85% confidence The document is a statutory disclosure (“신고”) of stock option grants under Korean regulatory rules, detailing option terms, recipients, and pricing. It does not provide financial statements or earnings results, nor is it an AGM material, call transcript, capital financing update, or share repurchase. It is not a director personal trade report or a standalone financial report. This falls under general regulatory/compliance filings. Therefore, it is classified as a Regulatory Filing (RNS).
2025-09-23 Korean
투자판단관련주요경영사항 (GXI7 관련 마일스톤 기술료 청구)
Regulatory Filings Classification · 100% confidence The document is a regulatory filing from Genexine regarding a 'Major Management Matter' (투자판단 관련 주요경영사항), specifically the receipt of a milestone payment related to a technology transfer agreement ('GX-I7'). This type of disclosure is a standard regulatory announcement in the Korean market (DART system) for material events that impact financial performance or contractual obligations. Since it does not fit into specific categories like M&A, dividends, or share issues, it falls under the general regulatory filing category.
2025-08-20 Korean
반기보고서 (2025.06)
Interim / Quarterly Report Classification · 100% confidence The document is a '반기보고서' (Semi-Annual Report) for the company '제넥신' (Genexine) covering the period from January 1, 2025, to June 30, 2025. It contains comprehensive financial statements, management discussion and analysis, and corporate governance information, which aligns with the definition of an Interim/Quarterly Report (IR). H1 2025
2025-08-14 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.